|
Arrowhead Pharmaceuticals ، Inc. (ARWR) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Arrowhead Pharmaceuticals, Inc. (ARWR) Bundle
تقييم التوقعات المالية Arrowhead Pharmaceuticals ، Inc. (ARWR) مثل خبير! تأتي حاسبة DCF (ARWR) هذه مع بيانات مالية محملة مسبقًا وتوفر لك المرونة لتعديل نمو الإيرادات ، WACC ، الهوامش ، وغيرها من الافتراضات الحرجة التي تتماشى مع توقعاتك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.0 | 138.3 | 243.2 | 240.7 | 3.6 | 3.8 | 4.2 | 4.5 | 4.9 | 5.3 |
| Revenue Growth, % | 0 | 57.16 | 75.89 | -1.03 | -98.52 | 8.37 | 8.37 | 8.37 | 8.37 | 8.37 |
| EBITDA | -87.2 | -132.6 | -162.3 | -175.7 | -561.5 | -3.3 | -3.6 | -3.9 | -4.3 | -4.6 |
| EBITDA, % | -99.12 | -95.87 | -66.72 | -72.97 | -15812.81 | -86.94 | -86.94 | -86.94 | -86.94 | -86.94 |
| Depreciation | 5.9 | 8.3 | 10.4 | 12.5 | 18.6 | .9 | 1.0 | 1.1 | 1.2 | 1.3 |
| Depreciation, % | 6.75 | 5.98 | 4.28 | 5.19 | 523.66 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 |
| EBIT | -93.2 | -140.8 | -172.7 | -188.2 | -580.1 | -3.5 | -3.7 | -4.1 | -4.4 | -4.8 |
| EBIT, % | -105.87 | -101.85 | -71.01 | -78.16 | -16336.47 | -89.83 | -89.83 | -89.83 | -89.83 | -89.83 |
| Total Cash | 315.5 | 367.8 | 376.4 | 403.6 | 681.0 | 3.8 | 4.2 | 4.5 | 4.9 | 5.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .8 | 10.3 | 1.4 | .0 | .0 | .1 | .1 | .1 | .1 | .1 |
| Account Receivables, % | 0.96108 | 7.42 | 0.5797 | 0 | 0 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 |
| Inventories | 4.3 | 4.4 | -21.6 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 4.83 | 3.15 | -8.89 | 0 | 0 | -0.18018 | -0.18018 | -0.18018 | -0.18018 | -0.18018 |
| Accounts Payable | 6.8 | 9.5 | 2.9 | 35.9 | 11.4 | 1.0 | 1.1 | 1.2 | 1.3 | 1.4 |
| Accounts Payable, % | 7.76 | 6.84 | 1.18 | 14.9 | 320.7 | 26.14 | 26.14 | 26.14 | 26.14 | 26.14 |
| Capital Expenditure | -12.0 | -23.6 | -52.8 | -176.7 | -141.5 | -1.7 | -1.9 | -2.0 | -2.2 | -2.4 |
| Capital Expenditure, % | -13.58 | -17.04 | -21.7 | -73.42 | -3983.92 | -45.15 | -45.15 | -45.15 | -45.15 | -45.15 |
| Tax Rate, % | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 |
| EBITAT | -93.2 | -140.8 | -176.5 | -187.1 | -567.8 | -3.4 | -3.7 | -4.0 | -4.4 | -4.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -97.4 | -163.0 | -190.6 | -338.5 | -715.2 | -14.7 | -4.5 | -4.9 | -5.3 | -5.7 |
| WACC, % | 8.14 | 8.14 | 8.14 | 8.14 | 8.12 | 8.14 | 8.14 | 8.14 | 8.14 | 8.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -29.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -6 | |||||||||
| Terminal Value | -95 | |||||||||
| Present Terminal Value | -65 | |||||||||
| Enterprise Value | -94 | |||||||||
| Net Debt | 408 | |||||||||
| Equity Value | -501 | |||||||||
| Diluted Shares Outstanding, MM | 120 | |||||||||
| Equity Value Per Share | -4.19 |
What You Will Get
- Pre-Filled Financial Model: Arrowhead Pharmaceuticals’ actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
- Instant Calculations: Automatic updates ensure you see results as you make changes.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Arrowhead Pharmaceuticals, Inc. (ARWR).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth rates, research and development expenses, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Arrowhead Pharmaceuticals, Inc. (ARWR).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.
How It Works
- Step 1: Download the Excel file for Arrowhead Pharmaceuticals, Inc. (ARWR).
- Step 2: Review Arrowhead's pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Arrowhead Pharmaceuticals, Inc. (ARWR)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for ARWR.
- Customizable Inputs: Modify the yellow-highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Arrowhead's intrinsic value and Net Present Value.
- Preloaded Data: Features historical and forecasted data for precise evaluations.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on ARWR.
Who Should Use This Product?
- Investors: Accurately assess Arrowhead Pharmaceuticals’ fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and strategic analysis.
- Consultants: Quickly customize the template for valuation reports tailored to clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation techniques.
What the Template Contains
- Historical Data: Includes Arrowhead Pharmaceuticals’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Arrowhead Pharmaceuticals’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Arrowhead Pharmaceuticals’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.